Table 4.
Association between clinical parameters and plasma levels of PUFA in PD.
ALA | EPA | DHA | LA | AA | n-6/n-3 ratioa | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ρ | P | ρ | p | ρ | p | ρ | p | ρ | p | ρ | p | |
Ageb | ||||||||||||
Disease duration, years | − 0.290 | 0.082 | − 0.030 | 0.861 | − 0.007 | 0.969 | − 0.116 | 0.493 | 0.019 | 0.910 | 0.159 | 0.349 |
WCS | − 0.101 | 0.552 | 0.001 | 0.996 | 0.008 | 0.963 | 0.184 | 0.276 | 0.183 | 0.279 | 0.165 | 0.329 |
K-NMSS | − 0.210 | 0.211 | − 0.227 | 0.176 | − 0.104 | 0.540 | − 0.173 | 0.306 | 0.211 | 0.210 | − 0.358 | 0.029 |
UPDRS I | 0.069 | 0.687 | 0.207 | 0.220 | 0.355 | 0.031 | − 0.203 | 0.229 | 0.362 | 0.028 | − 0.231 | 0.170 |
UPDRS II | − 0.056 | 0.742 | 0.198 | 0.241 | 0.258 | 0.123 | − 0.199 | 0.236 | 0.087 | 0.609 | − 0.025 | 0.886 |
UPDRS III | − 0.351 | 0.033 | − 0.185 | 0.272 | − 0.062 | 0.716 | − 0.424 | 0.009 | − 0.184 | 0.275 | − 0.149 | 0.380 |
H&Y stage | − 0.058 | 0.731 | 0.113 | 0.504 | 0.108 | 0.524 | − 0.038 | 0.824 | 0.183 | 0.279 | 0.053 | 0.757 |
LEDD, mg/d | − 0.187 | 0.269 | 0.005 | 0.978 | 0.172 | 0.308 | − 0.068 | 0.690 | 0.036 | 0.831 | 0.159 | 0.349 |
Sexc | ||||||||||||
Disease duration, years | − 0.273 | 0.102 | − 0.012 | 0.945 | 0.009 | 0.958 | − 0.110 | 0.518 | 0.034 | 0.840 | 0.135 | 0.424 |
WCS | − 0.103 | 0.546 | 0.003 | 0.985 | − 0.031 | 0.857 | 0.161 | 0.342 | 0.089 | 0.600 | 0.155 | 0.358 |
K-NMSS | − 0.191 | 0.257 | − 0.215 | 0.202 | − 0.052 | 0.761 | − 0.147 | 0.384 | 0.267 | 0.110 | − 0.351 | 0.033 |
UPDRS I | 0.101 | 0.552 | 0.221 | 0.189 | 0.441 | 0.006 | − 0.147 | 0.386 | 0.481 | 0.003 | − 0.244 | 0.145 |
UPDRS II | − 0.044 | 0.794 | 0.209 | 0.215 | 0.263 | 0.116 | − 0.194 | 0.251 | 0.089 | 0.601 | − 0.048 | 0.777 |
UPDRS III | − 0.349 | 0.034 | − 0.176 | 0.299 | − 0.066 | 0.699 | − 0.424 | 0.009 | − 0.178 | 0.293 | − 0.108 | 0.524 |
H&Y stage | − 0.134 | 0.427 | 0.082 | 0.628 | 0.065 | 0.700 | − 0.057 | 0.739 | 0.106 | 0.534 | 0.012 | 0.943 |
LEDD, mg/d | − 0.133 | 0.431 | 0.039 | 0.819 | 0.220 | 0.191 | − 0.047 | 0.784 | 0.100 | 0.555 | 0.135 | 0.424 |
Data are described as mean (standard deviation); the correlation coefficients and p values marked in bold indicate statistically significant differences.
Spearman’s partial correlation analysis was applied after adjusting for ageb and sexc.
PUFA polyunsaturated fatty acids, PD Parkinson’s disease, ALA alpha-linolenic acid, EPA eicosapentaenoic acid, DHA docosahexaenoic acid, LA linoleic acid, AA arachidonic acid, WCS Wexner constipation score, K-NMSS Korean Non-Motor Symptoms Scale, UPDRS Unified Parkinson’s Disease Rating Scale, H&Y stage Hoehn and Yahr stage, LEDD levodopa equivalent daily dose.
an-6/n-3 ratio = (LA + AA)/(ALA + EPA + DHA).